Head-to-head evidence
Apomorphine (Apokyn) vs LY03009
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine · full Parkinson's Disease pipeline
Apomorphine (Apokyn)
Marketed by Supernus Pharmaceuticals
NCT00142545 · Phase 3 · completed
The study was non-randomized, open-label, and had no comparator arm; all 800 participants received apomorphine. Its primary outcomes focused on safety monitoring, and no primary endpoint results were posted, so there is no controlled comparison showing benefit.
Next expected readout: December 2027 · NCT04957095 (registry estimate)
LY03009
Developed by Luye Pharma Group
NCT04593511 · Phase 1 · status unknown
This open-label, single-dose pharmacokinetic study compared four different formulations of LY03009 against each other in healthy volunteers, but included no placebo or inactive control arm and no blinding. No results have been posted, and because every arm receives active drug in a different formulation, this design cannot demonstrate a treatment effect once results are available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apomorphine (Apokyn)'s landscape · LY03009's landscape